NEW YORK, NY / ACCESSWIRE / February 16, 2016 / Q BioMed Inc. (OTCQB: QBIO) a biotechnology acceleration company, today
announced that the company will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at The
Ritz-Carlton in Miami on South Beach on February 22, 2016. Please click here for a list of presenting companies.
Each company will be provided with a 30-minute time slot to present to an audience of investors and industry professionals and
company management will also be available for one-on-one meetings with institutional investors.
Conference registration: complimentary for qualified investors and equity research analysts.
In order to register as an attendee of the conference, please click HERE.
To stay informed on Q BioMed developments please visit our website www.qbiomed.com and sign up for our news distribution.
About SeeThruEquity
Since the company's founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high
quality research on uncovered and undercovered microcap stocks and hosting investor conferences throughout the year. STE has been
able to grow its research universe to over 176 names.
STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because
it augments the conference experience with the firm's research which is part of Wall Street consensus and available across industry
leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE
has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4500 attendees and have included over
1,700 1-on-1 meetings. For more information please visit www.steconference.com.
About The Brewer Group
The Brewer Group, Inc. (TBG) is an industry agnostic investment and consulting company with assets ranging numerous sectors.
TBG's relationships with key international decision makers spanning government development agencies, financial institutions,
multinational corporations, NGOs and numerous leaders in sports and entertainment place TBG in a unique position to grow its
portfolio. TBG takes pride in identifying companies whose goal is to make a social impact on the communities in which they serve.
For further information, please visit www.thebrewergroup.com.
About Q BioMed Inc.
Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical
assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion
capital to ensure they meet their developmental potential enabling them to provide products to patients in need.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements
are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from
those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development
activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and
retain key personnel; the early stage of products under development; our need for substantial additional funds; government
regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We
expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements
contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Contact:
Denis Corin CEO Q BioMed Inc. 1 888 357 2435
SOURCE: Q BioMed Inc.
